IO Biotech

IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win technology platform. This platform represents a novel approach to cancer immunotherapy, designed to activate naturally occurring T cells that target both tumor cells and key immunosuppressive mechanisms within the tumor microenvironment, including cells expressing indoleamine 2,3-dehydrogenase (IDO), programmed death-ligand 1 (PD-L1), arginase 1, and TGF-β. The company's lead product candidate, IO102-IO103, also known as Cylembio, is in phase 3 clinical development for melanoma in combination with PD-1 inhibitors and is being evaluated in phase 2 trials for lung, head and neck cancers. Additional candidates include IO112, targeting arginase 1 in tumors associated with myeloid-derived suppressor cells such as renal cell carcinoma, breast, pancreatic, and prostate cancers, and IO170 for solid tumors. IO Biotech, Inc. focuses on off-the-shelf vaccines to address difficult-to-treat cancers across multiple solid tumor types. Founded in 2014 and headquartered in Copenhagen, Denmark, the company operates in the biotechnology sector, advancing immune-modulatory therapies to potentially enhance combination cancer treatments.